Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (1048)	2/23/1998 1:48:00 AM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

Cistron's total cash and cash receivables now stands at $13.3 million or 58 cents a share. Bluestone's last week! What is lacking in Cistron's stock price is proper support. An open market buyback from time to time would give the shareholders proper valuations on their assets.(think about it Cistron could buyback the entire float of 16 million shares at current prices for $4 million and still have $9.3 million in the kitty!) Cistron would then have 7 million shares outstanding(which would be CURRENT SHAREHOLDERS) with $9.3 million in cash or $1.33 a share in just cash! IL-1 is not used in the above valuation. It is currently not in Cistron's stock price anyway.